This Master Class program is a global initiative of the PACE-CME foundation with a particular focus on issues and opportunities in cardiovascular risk and lipid management in high risk patients

Agenda & Faculty

Cardiovascular Disease: The ongoing journey to manage the risk - University College London, London, United Kingdom

Managing CV Risk in Indonesia: How well are we doing and where can we improve? - Anwar Santoso, MD, University of Indonesia, Jakarta, Indonesia

Managing lipids: Integrating novel insights with gold standard therapies - Philip Barter, MD, University of Sydney, Sydney, Australia

Blood pressure: How do recent trial outcomes impact our hypertension management? - Neil Poulter, MD, Imperial College London, United Kingdom

Guidance in CV Risk management: How to deal with international guidelines? - Philip Barter, MD, Sydney, Australia

CV Risk guidelines for Indonesia: What and how to follow? - Renan Sukmawan, MD, Harapan Kita National Cardiovascular Centre, Jakarta-Indonesia

T2DM & CVD: An update on current and new strategies improving outcomes - Neil Poulter, MD, Imperial College London, United Kingdom

Educational information

The overall educational objectives of the Cardiovascular Master Class were to:

• review the epidemiology and current guidelines on the diagnosis, management, and treatment of patients at increased CV risk in Russia
• review new data on the pathophysiology of coronary artery disease and stroke and its relevance to treatment strategies and outcomes
• understand the medical need for intensive lipid and hypertension management in patients at high CV risk, such as DM and metabolic syndrome.
• understand the pharmacologic and clinical rationale for various treatment options in the patients with increased CV risk and integrate scientific evidence from key clinical trials into clinical practice
• Develop a consensus on practical guidelines for day-to-day management of high risk patients

CME accreditation

This Master Class was endorsed and accredited by the Indonesian Cardiology Association

Funding

The CV Risk Master Class was funded by an unrestricted educaional grant provided by Pfizer